Act A — The Enrollment Bottleneck
Fabry disease is a rare X-linked lysosomal storage disorder affecting approximately 1 in 40,000 people. A Phase II enzyme replacement therapy trial requires enrolled patients with confirmed GLA gene variants, established disease manifestation, and no prior exposure to the specific enzyme replacement product being tested — eligibility criteria that, combined with the disease prevalence, narrow the eligible patient pool to a very small number at any single site.
The economics of Fabry disease clinical research mean that most patients receiving treatment in Canada are concentrated at metabolic disease treatment centres affiliated with academic hospitals — precisely the sites most likely to have GCP-trained coordination infrastructure and regulatory inspection experience. There are perhaps eight to twelve such centres in Canada. The sponsor who identifies all of them in the first six weeks of site selection is running an unusually efficient process.
What a sponsor cannot easily learn from ClinicalTrials.gov or a published researcher directory is which of those centres has an active patient cohort that includes Fabry patients meeting the trial's specific eligibility criteria, not in treatment with a competing enzyme replacement product, and whose physician has bandwidth for a new sponsored trial.
Act B — The Story
Sasha's team spent four months on site identification. They searched ClinicalTrials.gov for prior Fabry disease trials, contacted metabolic disease societies, and followed researcher referrals from three already-identified Ontario sites. At the end of four months, they had five candidate sites, of which three had either no current active Fabry patient cohort at the required eligibility profile or no current site capacity for a new sponsored trial.
They activated two sites. Both were in Ontario. Enrollment at both sites was slower than projected — the combined Fabry patient cohort at enrollment eligibility was eighteen patients, of whom four had already been enrolled in a competing trial.
The platform had been live for eight months by that point. Dr. Amara had registered her Calgary metabolic disease centre profile three months earlier: Fabry disease treatment centre, 14 adult patients with confirmed GLA variants currently in enzyme replacement therapy follow-up, GCP-certified coordination team, two prior CIHR-funded trials, no currently active industry-sponsored trials.
Sasha's search on the platform — rare metabolic disease, Fabry, lysosomal storage, adult patients, Western Canada, GCP-trained site, no competing enrollment — returned Dr. Amara's profile as the third result.
Dr. Amara had been interested in industry-sponsored trials for three years. She had submitted two unsolicited expressions of interest to pharmaceutical companies through their medical affairs contact forms without response. Her patients had participated in a natural history registry study. She had the infrastructure, the cohort, and the interest. She lacked the visibility into the sponsor community that would have connected her to a trial for which her centre was an ideal site.
Dr. Amara's site was qualified in seven weeks. The Calgary site enrolled six patients in the first four months — the fastest-enrolling site in the trial.
The trial's primary endpoint was achieved on schedule. Without the Calgary site, enrollment projection at the original two-site design would have extended the Phase II by eleven months.
Act C — Why This Market Stays Broken Without Infrastructure
Dr. Amara's site was ideal in every dimension: patient cohort, infrastructure, staff, regulatory standing, and investigator interest. The information that defined her qualification as a site — Fabry patient cohort size, enzyme replacement follow-up experience, GCP certification, no competing enrollment — was not in any registry that Sasha's team searched during four months of site identification.
ClinicalTrials.gov indexes by prior registered trial. A site that has run only CIHR-funded trials — not industry-sponsored trials — is invisible in industry site selection unless it appears in a published researcher's CV or a metabolic disease society membership list. Dr. Amara appeared in neither, because she had published only in the European metabolic disease literature, not in the North American journals where her name would be findable by a clinical operations team doing English-language database searches.
Thin market infrastructure encodes the attributes that define site qualification — disease subtype cohort, infrastructure capability, GCP standing, enrollment capacity — into a searchable profile, at the moment the sponsor is in site selection and before the eleven months of enrollment delay accumulate.
Characters are fictional. Fabry disease prevalence, Canadian metabolic disease treatment centre structure, and GCP site qualification requirements under ICH E6 are real. DeeperPoint is building the infrastructure this story describes.